UY27376A1 - Formulación de medicamento que contiene un antagonista de ltb4 - Google Patents

Formulación de medicamento que contiene un antagonista de ltb4

Info

Publication number
UY27376A1
UY27376A1 UY27376A UY27376A UY27376A1 UY 27376 A1 UY27376 A1 UY 27376A1 UY 27376 A UY27376 A UY 27376A UY 27376 A UY27376 A UY 27376A UY 27376 A1 UY27376 A1 UY 27376A1
Authority
UY
Uruguay
Prior art keywords
formulation containing
ltb4 antagonist
medicinal formulation
ltb4
antagonist
Prior art date
Application number
UY27376A
Other languages
English (en)
Inventor
Dr R Becker
Dr T Bock
Siglinde Moll
Dr R Roscher
Dr U Roth
Dr A Sauer
Karl Weber
Original Assignee
Boehringer Ingelheim Pharma
Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10206241A external-priority patent/DE10206241A1/de
Application filed by Boehringer Ingelheim Pharma, Co Kg filed Critical Boehringer Ingelheim Pharma
Publication of UY27376A1 publication Critical patent/UY27376A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención se refiere a una nueva formulación de medicamento que contiene un antagonista de ltb4 de la fórmula I en donde A, R1, R", R3 y R4 presentan el significado indicado en la reivindicación 1, así como su empleo como medicamento.
UY27376A 2001-07-14 2002-07-11 Formulación de medicamento que contiene un antagonista de ltb4 UY27376A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10134377 2001-07-14
DE10206241A DE10206241A1 (de) 2001-07-14 2002-02-15 Arzneimittelformulierung enthaldend einen LTB Antagonisten

Publications (1)

Publication Number Publication Date
UY27376A1 true UY27376A1 (es) 2003-02-28

Family

ID=26009704

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27376A UY27376A1 (es) 2001-07-14 2002-07-11 Formulación de medicamento que contiene un antagonista de ltb4

Country Status (17)

Country Link
EP (1) EP1408943B1 (es)
JP (1) JP2005502630A (es)
KR (1) KR100912196B1 (es)
CN (1) CN1298316C (es)
AT (1) ATE298564T1 (es)
AU (1) AU2002333235B2 (es)
BR (1) BR0211090A (es)
CA (1) CA2452357A1 (es)
ES (1) ES2244821T3 (es)
HU (1) HUP0401371A3 (es)
IL (1) IL159493A0 (es)
MX (1) MXPA04000384A (es)
NZ (1) NZ530973A (es)
PL (1) PL368613A1 (es)
RU (1) RU2004102399A (es)
UY (1) UY27376A1 (es)
WO (1) WO2003007922A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232120A1 (de) 2002-07-16 2004-02-05 Fev Motorentechnik Gmbh Verfahren und Vorrichtung zum künstlichen Altern eines Kraftfahrzeugkatalysators
RS20050390A (en) * 2002-11-26 2008-04-04 Boehringer Ingelheim Pharma Gmbh. & Co.Kg., Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox 1/2 inhibitor
CA2560165A1 (en) * 2004-05-04 2005-11-10 Boehringer Ingelheim International Gmbh Solid pharmaceutical form comprising an ltb4 antagonist
AU2018266393A1 (en) 2017-05-12 2019-12-19 Riken Class A GPCR-binding compound modifier

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
HU216191B (hu) * 1992-02-05 1999-05-28 Boehringer Ingelheim Kg Eljárás új amidinszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DE4424713A1 (de) * 1994-07-13 1996-01-18 Boehringer Ingelheim Kg Substituierte Benzamidine, ihre Herstellung und Verwendung als Arnzneistoffe
DE19546452A1 (de) * 1995-12-13 1997-06-19 Boehringer Ingelheim Kg Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel
DE19636689A1 (de) * 1996-09-10 1998-03-12 Boehringer Ingelheim Kg Neue Benzamidinderivate
DE19637123A1 (de) * 1996-09-12 1998-03-19 Boehringer Ingelheim Kg Neue Pyranosidderivate
DE19948428A1 (de) * 1999-10-07 2001-04-12 Boehringer Ingelheim Pharma Neuer LTB¶4¶-Antagonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel

Also Published As

Publication number Publication date
NZ530973A (en) 2006-07-28
CN1527705A (zh) 2004-09-08
WO2003007922A3 (de) 2003-04-17
EP1408943A2 (de) 2004-04-21
MXPA04000384A (es) 2004-05-04
ES2244821T3 (es) 2005-12-16
WO2003007922A2 (de) 2003-01-30
JP2005502630A (ja) 2005-01-27
HUP0401371A2 (hu) 2004-12-28
KR20040016988A (ko) 2004-02-25
PL368613A1 (en) 2005-04-04
CA2452357A1 (en) 2003-01-30
AU2002333235B2 (en) 2007-07-12
KR100912196B1 (ko) 2009-08-14
CN1298316C (zh) 2007-02-07
EP1408943B1 (de) 2005-06-29
IL159493A0 (en) 2004-06-01
RU2004102399A (ru) 2005-05-27
ATE298564T1 (de) 2005-07-15
BR0211090A (pt) 2004-06-15
HUP0401371A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
SE0001899D0 (sv) New compounds
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
SE0300010D0 (sv) Novel Compounds
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
BR0211473A (pt) Novos compostos
SE0101387D0 (sv) Novel compounds
NO20065904L (no) Terapeutiske forbindelser
DE69907977D1 (de) Pyrrolobenzodiazepine
UY27368A1 (es) Nuevos compuestos
SE9504661D0 (sv) New compounds
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
HN2002000300A (es) Nuevos derivados de piperazina
RS99804A (en) Novel compounds and their use
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE9802206D0 (sv) Novel compounds
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302116D0 (sv) Novel compounds
SE0102055D0 (sv) New Compounds
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UY27376A1 (es) Formulación de medicamento que contiene un antagonista de ltb4
DE60005517D1 (de) Kaliumkanal-blockierende mittel
SE9504662D0 (sv) New compounds
AR023374A1 (es) Derivados de 3-amino-3-arilpropano-1-ol. su preparacion y uso

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141216